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AbstrAct
Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific 
inhibitors have been developed for melanoma treatment. Although these drugs induce 
tumor regression in a high percentage of patients, clinical responses are frequently 
limited in time and tumors often recur. Recent studies suggested that the combination 
of BRAF/MEK inhibition with immunotherapy could represent a promising strategy 
for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. 
Here we show that PLX4032 (a mutant BRAFV600 inhibitor) had no effect on the 
functional properties of NK cells cultured in the presence of IL-2 or IL-15. In contrast, 
PD0325901 (a MEK inhibitor) induced the down-regulation of the main activating NK 
receptors and inhibited NK cell function. Importantly, PD0325901 did not affect the 
anti-tumor activity of NK cells that had been exposed to a combination of IL-15 and 
IL-18. In addition, both PLX4032 and PD0325901 did not exert any inhibitory effect 
on in vitro IL-2 or IL-15 pre-activated NK cells. 
Our data may provide a rationale for future clinical protocols that combine IL-
15/IL-18 cytokine administration with MEK inhibitors. In addition, they suggest that 
oncogene-targeting drugs are compatible with NK-based adoptive therapy.
IntroductIon
Melanoma is a major world health problem with 
an incidence that is increasing at a rate faster than any 
other solid malignancy. The overall survival rate for 
patients with metastatic melanoma is poor and new 
forms of treatment are clearly needed. Approximately 
50% of cutaneous melanomas harbor a somatic mutation 
in the gene encoding BRAF, a serine/threonine protein 
kinase that activates the mitogen-activated protein 
kinase (MAPK)/ERK-signaling pathway [1]. Among the 
BRAF mutations detected in melanoma, over 80% are 
represented by a single nucleotide mutation characterized 
by a glutamic acid for valine at codon 600 (BRAFV600E). 
BRAF mutations lead to constitutive activation of 
the MAPK signaling pathway involved in different 
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mechanisms of tumor progression including evasion of 
apoptosis, unchecked cell replication, neoangiogenesis, 
tissue invasion, metastasis as well as escape from immune 
response [2].
The identification of BRAF mutations offered an 
opportunity to test novel oncogene-targeted therapies for 
melanoma. In particular, PLX4032 (a highly active agent 
for the treatment of BRAFV600 mutant melanoma) has been 
found to induce tumor regression in high percentages of 
patients with BRAFV600E-positive metastatic melanoma. 
However, clinical responses were limited in time (less 
than 12 months) in most patients [3]. The emergence of 
resistance may reflect reactivation of MAPK pathway 
due to new mutations [4-6] or activation of alternative 
pathways involving MAPK and PI3K/Akt [7, 8]. In 
particular, analysis of clinical specimens and cell lines 
resistant to the selective BRAF inhibitor (BRAF-i) 
allowed to identify a variety of molecular mechanisms that 
reactivate signaling via MEK and ERK. In view of these 
limitations, new protocols have been designed in which 
BRAF-targeted therapies have been associated with MEK 
inhibitors (MEK-i), such as Trametinib [9] or Cobimetinib 
[10]. Since also immunotherapy may induce long lasting 
responses [11], an area of ongoing investigation involves 
the combination of BRAF-i/MEK-i with immune-
based therapies. However, the efficacy of cell-based 
immunotherapy, due to the potent anti-tumor activity of 
both cytolytic T lymphocytes (CTL) and natural killer 
(NK) cells, may be compromised by the simultaneous use 
of oncogene-targeted therapies. In this context, in order to 
efficiently combine kinase inhibitors with immunotherapy, 
it is critical to assess whether these drugs may influence 
the effector cell responses. It has been shown that 
inhibition of the MAPK pathway using PLX4720 (a 
selective inhibitor of BRAFV600E) did not affect the 
viability and function of T cells. In addition, it induced 
an increased expression of melanocyte differentiation 
antigens (MDAs), thus conferring a more potent antigen-
specific cytotoxicity to CTL [12]. Other studies showed 
that BRAF inhibition resulted in an improved infiltration 
of adoptively-transferred T cells in vivo, thus enhancing 
the anti-tumor activity of adoptive cell transfer (ACT) 
therapy [13]. In contrast, MEK inhibition had a similar 
effect on MDAs [12], but affected multiple functions of in 
vitro isolated T-lymphocytes [12, 14]. However, in contrast 
with in vitro data, in vivo studies suggest that MEK-i do 
not interfere with the anti-tumor activity of T-cell-based 
therapy [15] or of specific immunomodulatory antibodies 
targeting PD-1, PD-L1 and CTLA-4 [16]. Recently, it 
has been demonstrated that in vivo MEKi, when used in 
combination with PD-L1 checkpoint blockade, potentiate 
T-cell-mediated anti-tumor immunity by increasing the 
frequency of intratumoral antigen-specific effector CD8+ 
T cells [17].
Besides specific T lymphocytes, it is now well 
established that also NK cells play a role in cancer 
immune-surveillance. Indeed, individuals with high NK 
cell activity have been shown to display a reduced risk of 
developing cancer [18]. In addition, in different human 
and murine tumors, a high level of NK cell infiltration 
correlates with a better prognosis [19-21].
The process of NK cell activation is the result of 
a fine balance between signals mediated by an array of 
triggering and inhibitory surface receptors [22-24]. The 
NK cell receptors involved in tumor cell killing include 
the HLA class I-specific inhibitory receptors (i.e. KIRs 
and CD94/NKG2A) and major activating NK receptors 
(including NKp30, NKp46, NKp44, NKG2D and DNAM-
1). In the absence of inhibitory signals the interaction 
between activating receptors and their specific ligands on 
tumor cells results in NK cell triggering and target cell 
lysis. The main ligands of activating NK receptors include 
MICA/B, ULBPs (recognized by NKG2D) [25, 26] 
Nectin-2 and PVR (recognized by DNAM-1) [27], B7H6 
(recognized by NKp30) [28, 29] and a novel isoform of 
the mixed-lineage leukemia-5 protein (MLL5) (recognized 
by NKp44) [30]. In most instances, these ligands are not 
(or only marginally) expressed by normal resting cells 
while they become highly expressed on tumor cells. It has 
been shown that melanoma cells are susceptible to lysis 
by IL-2-activated NK cells. This effect is consequent both 
to down-regulation of MHC class I antigens and to the 
expression of ligands of activating NK receptors on tumor 
cells.
The actual efficacy of combination treatments 
involving MAPK inhibitors and NK cell-based 
immunotherapy, as well as the occurrence of possible 
interference with NK cell function, remains to be fully 
clarified. A study in mice showed a significant enrichment 
in intratumoral NK1.1+ NK cells after treatment with the 
BRAF-i PLX4720 [31]. Along this line, murine NK cells 
have been shown to play a critical role in favoring the 
anti-metastatic effect of BRAF inhibitors [32]. However, 
limited information is available on whether BRAF-i and 
MEK-i may directly affect human NK cells [32, 33].
In this study, we show that PLX4032, a selective 
BRAF-i, has no inhibitory effect either on NK cell 
proliferation in response to cytokines (including IL-
2, IL-15, and IL15 plus IL-18) or on NK cell function 
(cytotoxicity and cytokine production). PD0325901 has a 
negative effect on NK cells exposed to IL-2 and IL-15, 
but not on NK cells treated with IL-15/IL-18. In view of 
the possibility to combine adoptive immunotherapy with 
in vitro expanded NK cells and BRAF-i and/or MEK-i, we 
further evaluated their possible interference with cytokine-
pre-activated NK cells. Importantly, our data indicate that 
both BRAF-i and MEK-i do not exert any inhibitory effect 
on both IL-2- and IL-15- pre-activated NK-cells. 
Thus, our study provides a clue for designing 
future therapies that combine IL-15/IL-18 cytokine 




effect of brAF-i and MeK-i on nK cell survival
We first analyzed the effect of selective inhibitors 
of BRAF (PLX4032) or MEK (PD0325901) on NK cell 
viability. To this end, NK cells, freshly isolated from 
peripheral blood (PB) of healthy donors, were cultured 
in IL-2 in the presence of PLX4032 and PD0325901 at 
4 different drug concentrations (100µM, 10µM, 1µM, 
and 0.1µM). After 5 days, the percentages of early 
apoptotic (Annexin V+/PI-), late apoptotic (Annexin V+/
PI+), and necrotic cells (Annexin V-/ PI+) were evaluated 
in both treated and untreated cultured NK cells. Annexin 
V/PI staining revealed a markedly different pattern of 
susceptibility of NK cells to BRAF-i and MEK-i. As 
shown in Figure 1A, NK cells cultured in the presence of 
high concentrations (100µM) of PLX4032 showed a poor 
viability, whereas those treated with 100µM PD0325901 
Figure 1: survival of nK cells exposed to increasing concentrations of either brAF-i or MeK-i. Percentage of apoptotic/
necrotic cells upon treatment with PLX4032 or PD0325901. NK cells obtained from 3 healthy donors were cultured for 5 days with IL-2 
in the presence of different concentrations (100µM, 10µM, 1µM and 0.1µM) of the drugs. NK cells cultured with IL-2 in the presence of 
DMSO represent the negative controls. A. Representative flow cytometric analysis based on ANN-V and PI staining of NK cells either 
untreated (DMSO) or treated with PLX4032 or PD0325901 (100µM and 10µM). Numbers indicate the percentage of cells in each quadrant. 
b. Percentage of apoptotic/necrotic (ANN-V+ PI-, ANN-V+PI+, and ANN-V-PI+) NK cells either untreated (DMSO) or exposed to the 
indicated drug concentrations. Results are obtained from 3 independent experiments. Each point represent mean ± SD. **, p < 0.01; n.s., 
not significant by two tailed paired Student’s t test. 
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were not significantly affected. On the other hand, 10µM 
or lower concentrations (1µM-0.1µM) of either BRAF-i 
or MEK-i did not affect NK cell viability (Figure 1A, and 
data not shown). Figure 1B shows the statistical analysis 
of the experiments performed using NK cells isolated from 
3 different donors and treated with graded concentrations 
(100µM, 10µM, 1µM, and 0.1µM) of PLX4032 or 
PD0325901. These results show that NK cells survive up 
to 10µM concentrations of BRAF-i and MEK-i. 
effect of brAF-i and MeK-i on the expression of 
activating nK receptors
We investigated the effect of BRAF-i and MEK-i 
on the expression of activating NK receptors/co-
receptors that have been shown to play a major role in 
NK-mediated melanoma cell lysis (i.e. NKp46, NKp30, 
NKG2D and DNAM-1) [34-36]. NK cells isolated from 
healthy donors were stimulated, in the presence of either 
BRAF-i (PLX4032) or MEK-i (PD0325901), with IL-
2, IL-15 or the combination of IL-15/IL-18. We have 
chosen this cytokine combination since IL-18 signaling 
potentiates NK cell effector function by synergizing with 
common γ chain cytokines [37]. In addition, it has been 
shown that peripheral blood NK cells are very rapidly 
and significantly activated with the combination of IL-15 
and IL-18 [38]. The oncogene-targeting drugs were used 
at a concentration of 10 µM (non toxic for NK cells, see 
Figure 1) because most melanoma cell lines, displaying 
BRAFV600 mutations, are susceptible to PLX4032 in a 
range between 1µM and 10µM (Figure S1). The surface 
expression of activating receptors was analyzed by flow 
cytometry both in freshly isolated and cultured NK cells (3 
days culture with cytokines either in the absence or in the 
presence of the drugs). In agreement with previous data, 
NK cells cultured in IL-2 or IL-15 displayed an increased 
expression of NKp30 and NKG2D. The activation 
marker CD69 (used as control) was expressed de novo. 
In the presence of PD0325901 the expression of NKp30, 
NKG2D and CD69 was markedly lower than in control 
NK cells, while PLX4032 had virtually no effect. The 
surface density of NKp46 and DNAM-1 was virtually 
unchanged. Also the expression of Killer cell Ig-like 
receptors (KIRs) (including KIR2DL1/S1, KIR2DL2/L3/
S2, KIR3DL1/S1) and CD94/NKG2A was not modified 
in the presence of the various inhibitors (data not shown). 
NK cells cultured with IL-15/IL-18 displayed a lower 
expression of NKp30 and NKG2D as compared to NK 
cells cultured with IL-2 or IL-15 alone. The presence 
of either BRAF-i or MEK-i did not modify the levels 
of expression of NKp30 and NKG2D in IL-15/IL-18 
NK cells, possibly due to the low levels of expression 
of these activating receptors. Of note, CD69 was highly 
expressed by IL-15/IL-18 NK cells also in the presence of 
PD0325901 (Figure 2A).
Finally, the Fc-γ receptor CD16 was similarly 
expressed in NK cells cultured in IL-2 or IL-15 either 
alone or in the presence of the drugs. On the other hand, 
NK cells cultured with IL-15/IL-18, either alone or in the 
presence of PLX4032 displayed a reduced expression 
CD16. While PD0325901- treated IL-15/IL-18 NK cells 
maintained the expression of CD16 (Figure 2A). 
The morphology of NK cells exposed to the drugs 
was analyzed by light microscopy (Figure 2A, photos on 
the right). NK cells treated with cytokines and BRAF-i 
exhibited morphological characteristics of activated NK 
cells (i.e. presence of small cell clumps). When NK cells 
were treated with IL-2 or IL-15 in the presence of MEKi, 
they displayed the morphologic characteristic of resting 
cells (absence of cell clumps), whereas with IL-15/IL-18 
cells were grouped in clumps. We analyzed the expression 
of cellular adhesion molecules (CAM), CD54/ICAM-1, 
CD58/LFA-3, CD18 and CD2 in MEKi-treated NK cells. 
NK cells cultured with IL-15/IL-18 in the presence of 
PD0325901, expressed CD54/ICAM-1 at a higher density 
than drug-treated NK cells cultured with IL-2 or IL-15 
alone. In addition, a trend toward an increase of CD58/
LFA-3 and CD18 expression is observed in PD0325901-
treated IL-15/IL-18 NK cells, while the percentage of CD2 
expressing NK cells did not change (Figure S2). 
Statistical analysis confirmed that MEK-i, but 
not BRAF-i, downregulated the expression of NKp30, 
NKG2D and CD69 in NK cells cultured with IL-2 or IL-
15 alone, while such effect was not detected in NK cells 
cultured with IL-15/IL-18. In addition, PD0325901, but 
not PLX4032, prevented CD16 downregulation induced 
by IL-15/IL-18 (Figure 2B).
effect of MeK-i and brAF-i on cytokine-induced 
nK cell proliferation
We next analyzed the effect of BRAF-i and MEK-i 
on the cytokine-induced NK cell proliferation. In these 
experiments, NK cells were cultured with IL-2, IL-15 
or IL-15/IL-18 either in the absence or in the presence 
of inhibitors. After 6 days, the expression of Ki-67, a 
cell-cycle-associated antigen exclusively expressed in 
proliferating cells, was assessed (Figure 3A). BRAF-i 
(PLX4032) had no effect on NK cell proliferation, whereas 
MEK-i (PD0325901) strongly inhibited proliferation of 
NK cells activated with IL-2 or IL-15. Of note, MEK-i 
did not reduce the proportion of proliferating NK cells in 
the presence of IL-15/IL-18. Statistical analysis confirmed 
the data (Figure 3B).
effect of MeK-i and brAF-i on nK cell cytoxicity 
and cytokine production
NK cells, cultured with IL-2, IL-15 or IL-15/IL-
18 and in the presence of either BRAF-i or MEK-i, were 
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Figure 2: effect of brAF-i and MeK-i on nK cell receptor expression. Surface phenotype of NK cells isolated from 4 healthy 
donors cultured for 3 days with IL-2, IL-15 or IL15/IL-18 either in the absence (DMSO) or in the presence of PLX4032 and PD0325901 
(10 µM). A. Expression of the main activating receptors (black histograms) was analyzed by fluorescence-activated cell sorting on NK 
cells freshly isolated (t0) or cultured (day 3) with the indicated cytokines either in the absence or in the presence of the drugs. Gray profiles 
represent negative controls. Numbers indicate MRFI (or the % of CD16+ NK cells). A representative experiment out of 4 performed is 
shown. The morphological aspect of NK cells upon treatment with the indicated drugs is shown by light microscopy photos on the right 
(Microscope Leica DM LB2) b. Statistical analysis of the expression of NKp30, NKG2D, CD69 and CD16 on NK cells cultured either 
alone (black bars) and in the presence of PLX4032 (gray bars) or PD0325901 (white bars). Results are obtained from 4 independent 
experiments. Results are represented as mean of MRFIs (or as % of CD16+ cells) ± SEM. **, p < 0.01*, p < 0.05; by Student’s t test. 
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analyzed for their ability to kill different melanoma cell 
lines including MeCoP, MeTA, MeDeBO and FO-1. While 
BRAF-i had no substantial effect, MEK-i sharply reduced 
tumor cell lysis mediated by IL-2- and IL-15-activated NK 
cells. On the other hand, NK cells cultured with IL-15/IL-
18 maintained their cytolytic activity against melanoma 
targets in the presence of both inhibitors (Figure 4A). 
Statistical analysis confirmed the significance of these 
data (Figure 4B). Statistical significance was maintained 
at different effector-to-target ratios (5:1, 2.5:1 and 1.25:1) 
(not shown). 
We next assessed the effect of different 
concentrations of PD0325901 on NK cells cultured with 
IL-2, IL-15 or IL-15/IL-18. To this end, NK cells were 
exposed for 3 days to different MEK-i concentrations 
(10μM, 1μM and 0.1μM) and then analyzed for CD69 
expression and anti-tumor killing capability (Figure S3). 
Even in the presence of low drug doses (i.e. 1μM and 
0.1μM), NK cells cultured with IL-2 or IL-15 displayed 
a markedly lower expression of CD69 than control NK 
cells (Figure S3, panel A). Also their killing capability 
was decreased in a dose dependent manner as compared 
with untreated cells (Figure S3, panel B). On the other 
hand, when NK cells were cultured with IL-15/IL-18, 
PD0325901 only marginally affected the expression of 
CD69. In addition, the cytolytic activity of IL-15/IL-
18 cultured NK cells was unmodified by PD0325901, 
regardless of the concentration used (Figure S3, panel B). 
In order to investigate whether IFN-γ production 
was affected by MEK-i and BRAF-i, NK cells were 
cultured for 3 days with IL-2, IL-15 and IL-15/IL-18 in the 
presence or absence of the drugs. In all NK cell cultures 
containing BRAF-i, IFN-γ was produced in amounts 
comparable to controls. In contrast, IFN-γ production 
was abolished in IL-2- or IL-15-cultured NK cells in the 
presence of MEK-i. NK cells cultured with IL-15/IL-18 
were able to release higher amounts of IFNγ (as compared 
to IL-2 or IL-15-cultured NK cells). Of note, PD0325901 
impaired but not completely abolished the IL-15/IL-18-
induced IFN-γ production (Figure 4C). 
Finally, given that combined inhibition of BRAF/
MEK is associated with improved clinical outcomes 
among patients with BRAF V600-mutated metastatic 
melanoma [10], we further assessed whether the addition 
Figure 3: effect of brAF-i and MeK-i on nK cell proliferation. Proliferative responses of NK cells isolated from 4 healthy 
donors cultured for 6 days with IL-2, IL-15 or IL-15/18 either in the absence (DMSO) or in the presence of PLX4032 or PD0325901 (10 
µM). A. Representative flow cytometric analysis showing proliferating NK cells either untreated (red profiles) or exposed to PLX4032 (blue 
profiles) or PD0325901 (black profiles) expressing Ki67 are shown. Numbers indicate the percentages of proliferating cells. b. Statistical 
analysis of NK cell proliferation induced by cytokines in the absence or in the presence of BRAF-i (PLX4032) or MEK-i (PD0325901). 
Data are shown as means ± SD. Data are representative of 4 independent experiments. **, p < 0.01*, p ≤ 0.05; n.s., not significant by two 
tailed paired Student’s t test.
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Figure 4: effect of brAF-i and MeK-i on nK cell function. A. Cytotoxic activity of untreated or treated NK cells cultured for 
3 days with the indicated cytokines against different melanoma cell lines (MeCoP, MeTA, MeDeBO, FO-1). Results of a representative 
experiment out of 3 performed are shown. Data represent the percentage of lysis mediated by NK cells. b. Overall cytolytic activity 
mediated by NK cells cultured with different cytokines in the absence (black bar) or in the presence of PLX4032 (gray bars) or PD0325901 
(white bars) against the 4 melanoma cell lines indicated in panel A. The E:T ratio was 10:1. Bars represent means ± SD obtained from 3 
independent experiments. **, p ≤ 0.01; n.s., not significant by two tailed paired Student’s t test. c. IFNγ release by NK cells cultured with 
IL-2, IL-15 or IL-15/IL-18 either in the absence (black bar) or in the presence of PLX4032 (gray bars) or PD0325901 (white bars). Results 
are represented as means ± SEM obtained from 4 independent experiments. *, p < 0.05 by two tailed paired Student’s t test.
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of IL-18 to IL-15 was also able to rescue NK suppression 
induced by BRAF/MEK co-inhibition. Thus, NK cells 
cultured with IL-15/IL-18 and exposed simultaneously 
to both drugs were analyzed for their anti-tumor activity 
and proliferative capability (Figure S4). The NK-mediated 
cytotoxicity against melanoma cell lines (Figure S4, 
panels A and B), as well as cytokine-induced proliferation 
(Figure S4 panel C), was not impaired. 
both MeK-i and brAF-i are compatible with 
protocols of nK-based adoptive immunotherapy
In the experiments described above, PB NK cells 
were cultured with IL-2, IL-15 or IL-15/IL-18 and the 
inhibitors were added at the beginning of the culture. 
Since IL-2- and IL-15- pre-activated NK cells may be 
used in protocols of adoptive immunotherapy in cancer 
patients, we further investigated the effect of BRAF-i 
and MEK-i on NK cells that had been pre-activated for 
2 days with IL-2 or IL-15. To this end, NK cells isolated 
from healthy donors were cultured in the presence of IL-2 
Figure 5: effect of brAF-i and MeK-i on Il-2- or Il-15- pre-activated nK cells. Phenotypic and functional analysis of 
NK cells activated for 2 days with IL-2 or IL-15 (pre-activated NK cells) and then treated overnight (o/n) with PLX4032, PD0325901 
or DMSO as control. A. Immunofluorescence analysis was done on freshly isolated NK cells (t0) and on cytokine pre-activated NK cells 
(day 2) exposed to the indicated drugs. Markers expression was analyzed with mAbs to the indicated molecules (filled gray histograms). 
White histograms represent negative controls. Numbers indicate the MRFI for each receptor. Results of a representative experiment out of 3 
performed are shown. b. Cytolytic activity of pre-activated NK cells (2 days) either untreated (DMSO) or treated o/n with the drugs against 
a melanoma cell line (MeTA). Data represent the percentage of lysis by untreated or treated NK cells. Results are represented as means ± 
SEM obtained from 3 independent experiments. n.s., not significant by two tailed paired Student’s t test.
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or IL-15 for 2 days and further treated overnight (o/n) 
with either BRAF-i or MEK-i. The phenotypic analysis 
was focalized on the expression of NKp30, NKG2D and 
CD69, as it was markedly impaired in freshly isolated 
NK cells cultured with IL-2 or IL-15 in the presence of 
PD0325901 (see above). As shown in Figure 5A, neither 
BRAF-i nor MEK-i had any effect on the expression of 
NKp30 NKG2D, and CD69. In addition, the cytolytic 
activity of IL-2 or IL-15-pre-activated NK cells was not 
impaired in the presence of both drugs (Figure 5B and 
Figure S6). On the other hand, PD0325901 was able 
to inhibit the cytotoxicity of freshly isolated NK cells 
cultured overnight (o/n) in the presence of IL-2 or IL-
15 (Figure S5). These data suggest that both PLX4032 
and PD0325901 may be combined with NK cell-based 
adoptive immunotherapeutic strategies without affecting 
the efficacy of IL-2 or IL-15-pre-activated NK cells. 
dIscussIon
In this study we show that while the BRAF-i 
PLX4032 had no significant effect, the MEK-i PD0325901 
strongly inhibited the surface expression of the main 
activating receptors and the anti-tumor activity of freshly 
isolated NK cells cultured with IL-2 or IL-15. Importantly, 
no functional inhibition occurred in NK cells exposed to 
a combination of IL-15 and IL-18. While in IL-15/IL-18 
untreated and in BRAFi-treated NK cells only a small 
fraction of cells expressed CD16, the large majority of 
IL-15/IL-18 MEKi-treated cells expressed this marker, 
thus allowing MEKi-treated NK cells to preserve 
their capability of mediating antibody-dependent cell 
cytotoxicity (ADCC). Interestingly, both inhibitors had no 
effect when added to NK cells pre-activated with IL-2 or 
IL-15, thus offering an important clue for the development 
of novel therapeutic strategies combining BRAF/MEK 
inhibitors with adoptive NK cell therapy. 
The identification of activating somatic mutations 
in serine-threonine protein kinase BRAF (BRAFV600E) 
in 50% of patients with advanced melanoma offered 
the opportunity to develop oncogene-targeted therapies 
for this tumor. To date, different kinase inhibitors that 
target the constitutive up-regulated MAPK pathway 
have been generated and applied in clinical trials in the 
cure of melanoma. In particular, the administration of 
the BRAFV600-i Vemurafenib (PLX4032) or the MEK-i 
Trametinib resulted in an increased overall survival as 
compared to conventional chemotherapy [39-41]. The 
anti-tumor effect achieved with BRAF-i or MEK-i is 
primarily exerted on melanoma cells, resulting in marked 
shrinkage of tumor lesions consequent to apoptotic cell 
death. However, despite the encouraging response rates 
(ranging from 20 to 50%) and the impact on patient 
survival, in most cases responses to BRAF-i or MEK-i are 
transient [42]. Thus, the development of drug resistance 
eventually leads to tumor relapses.
Different immunotherapeutic approaches, including 
IL-2 therapy, and adoptive T cell transfer achieved 
promising results with a substantial clinical benefit at 
least in a fraction of melanoma patients [43]. Thus, it is 
conceivable that protocols that combine immune-based 
therapies with kinase inhibitors may result effective 
and thus need to be further explored. Along this line, 
recent evidences suggested that inhibition of the MAPK 
pathway in melanoma cells may result in the block of 
the production of tumor-derived immunosuppressive or 
proangiogenetic factors including IL-6, IL-10 and VEGF 
that are essential for cancer immune evasion and growth 
[44]. Other studies suggested that BRAF inhibition leads 
to increases of tumor infiltrating T cells in melanoma and 
induces the up-regulation of the melanoma differentiation 
antigens (MDA) in tumor cells [12]. These data support 
the notion that BRAF-targeted therapies may be used in 
association with T cell-based immunotherapy. Notably, 
however, a recent assessment of infiltrating T cells showed 
that they are characterized by an “exhausted phenotype” 
as revealed by an increased expression of PD-1 and its 
immunosuppressive ligand PD-L1 [45].
Also NK cells may represent powerful effectors 
against tumor as indicated by recent studies in patients 
with high-risk leukemia [46]. These studies provided 
clear evidence for a major role of NK cells in the cure 
of these malignancies in the haploidentical Hematopoietic 
Stem Cell transplantation setting. NK cells (derived 
from donor’s CD34+ precursors) that express KIRs, 
mismatched with their HLA ligands in the donor versus 
recipient direction, clear leukemia blasts residual after the 
conditioning regimen, thus preventing leukemia relapses. 
In addition, a novel approach based on the depletion of 
TCR α/β+ T cells and B cells in which fresh alloreactive 
NK cells are infused together with CD34+ cells supports 
the notion that also fresh NK cells may represent suitable 
effectors against leukemia. Clinical results strongly 
support the notion that NK cells may indeed represent 
a powerful tool in tumor immunotherapy. Thus, it is 
conceivable that NK-based immunotherapy may be 
adopted also for the therapy of solid tumors, in particular 
melanoma. 
Melanomas frequently lose the surface expression 
of MHC class I molecules thus acquiring resistance to 
MHC-restricted recognition by conventional T cells. This, 
together with the frequent expression on melanoma cells 
of ligands recognized by major activating NK receptors 
(including MICA/B, ULBPs, PVR, Nectin-2 and B7H6) 
[34-36, 47], suggests that NK cells may indeed represent 
important effectors against this tumor. 
Thus, our study was designed to analyze whether 
different inhibitors of the MAPK pathway could interfere 
with the NK cell function. Indeed, we found that the 
MEK-i PD0325901 could sharply inhibit both cytolytic 
activity and NK cell proliferation in response to IL-2 or 
IL-15. On the other hand, the specific kinase inhibitor 
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PLX4032 that targets mutated BRAF did not significantly 
alter IL-2- and IL-15-induced NK cell proliferation 
and cytolytic activity. Notably, IL-15/IL-18 cytokine 
combination spared the cytotoxic activity and proliferation 
of NK cells exposed to MEK-targeted agents. Thus, our 
data suggest that IL-15 and IL-18 cytokines could be 
utilized in combination with BRAF/MEK inhibitors to 
sustain and/or activate NK cell anti-tumor potential in 
vivo. 
Although the intracellular mediators involved in 
the regulation of NKG2D ligands expression are still 
unknown, preliminary data would indicate that the MEK1/
ERK, p38 MAPK, PI3K/Akt signaling pathways are 
involved in MICA and MICB up-regulation in cancer [48, 
49]. These results suggest that BRAF-i and MEK-i may 
influence cancer susceptibility to NK cells. Opposite data 
have been reported regarding the susceptibility to NK cell-
mediated killing of tumor cells resistant to kinase-target 
drugs [50, 51]. In vitro data would suggest that during 
the acquisition of BRAF-i resistance, tumor cells develop 
cross-resistance to NK-mediated lysis [51]. However, it 
has been shown that thyroid tumor cells, characterized by 
a constitutive activation of the MAPK pathway (due to the 
mutations of oncogenes such as RAS, BRAF, and RET/
PTC), are more susceptible to NK cell-mediated killing. 
Notably, these BRAF-mutated tumor cells express the 
NKG2D ligands MICA/B at a higher level than unmutated 
tumors as a consequence of the activation of the MAPK 
pathway [50]. Moreover, a common mechanism by which 
tumor cells may by-pass the inhibitory effect exerted 
by RAF is the re-activation of the MAPK pathway by 
MEK and ERK signaling [52]. These data suggest that 
tumor cells resistant to BRAF-i may overexpress ligands 
recognized by activating NK receptors as a consequence 
of the MAPK pathway activation, thus becoming more 
sensitive to NK-mediated lysis. 
In conclusion, our data also indicate that both the 
MEK-i PD0325901 and the BRAF-i PLX4032 do not exert 
any inhibitory effect on IL-2 or IL-15 pre-activated NK 
cells, thus suggesting that NK cell-based immunotherapy, 
used in combination with BRAF/MEK inhibitors, may 




The following monoclonal antibodies (mAbs) were 
used in this study: PE-conjugated anti-NKp46 (clone 
BAB281/IgG1, PN IM3711), PE-anti-NKp30 (clone Z25/
IgG1, PN IM3709), PE-anti-NKp44 (clone Z231/IgG1, 
PN IM3710), PC5-anti-CD56 (clone N901-NKH-1/IgG1, 
PN A79388) were from Beckman Coulter. PE-anti-CD16 
(clone VEP13/IgM, 130-091-245), PE-anti-NKG2D 
(clone BAT221/IgG1, 130-092-672), PE-anti-CD69 
(clone FN50/IgG1, 130-092-160), FITC-anti-CD3 (clone 
BW264/56/IgG2a, 130-080-401) were from Miltenyi 
Biotec. PE-anti-DNAM-1 (clone 11A8/IgG1, 338306) 
was from Biolegend. Alexa Fluor 647-Anti-human Ki-67 
(clone B56/IgG1, 558615) was from BD.
Flow-cytofluorimetric analysis
For cytofluorimetric analysis cells were stained with 
the appropriate labeled mAbs. To compare the surface 
densities of NK receptors among NK cells cultured in 
the presence or in the absence of BRAF-i or MEK-i the 
mean ratio fluorescence intensity (MRFI) was calculated; 
that is the ratio between the mean fluorescence intensity 
(MFI) of cells stained with the selected mAb and the MFI 
of unstained cells. Data analyses were performed using 
FlowJo software (TreeStar Inc.). 
nK cell isolation and culture
NK cells were isolated from peripheral blood 
mononuclear cells (PBMCs) using the Human NK Cell 
Enrichment Cocktail-RosetteSep (StemCell Technologies 
Inc., 15065). Only populations displaying more than 95% 
of CD56+ CD3- CD14- NK cells were selected for the 
experiments. The isolated NK cells were cultured for 3 or 
5 days in complete medium: RPMI 1640 (Lonza, 12-167F) 
10% plus AB serum (Biowest, S4190-100), 1% penicillin/
streptomycin (Lonza, 17-602E), 1% glutamine (Lonza, 
17-605E) with 100U/ml IL-2 (Proleukin, Novartis), with 
20ng/ml IL-15 (Miltenyi Biotech, 130-093-955), or with 
20ng/ml IL-15 plus 0.1µg/ml IL-18 (MBL, B001-5) [53], 
in the presence or in the absence of BRAF-i (PLX4032, 
S1267) or MEK-i (PD0325901, S1036) (Selleckchem) 
dissolved in DMSO. All experiments were performed 
in accordance with approvals from the Liguria Regional 
Committee.
Apoptosis analysis
NK cells were cultured for 5 days in complete 
medium with 100U/ml IL-2 and treated with increasing 
concentrations of BRAF-i (PLX4032) or MEK-i 
(PD0325901) dissolved in DMSO or with DMSO as 
negative control. The cells were transferred to FACS tubes 
and stained with Annexin V and propidium iodide (PI) 
following the manufacturer’s instructions (Immunostep, 
ANXVKF-100T) and analyzed by flow cytometry. 
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Mtt assay
NK cells (2x106/ml) and melanoma cells (5x104-
2.5x104/ml) were cultured in 96-well U-bottom plates in 
complete medium either in the presence or in the absence 
of different concentrations of PLX4032. NK cell culture 
medium was supplemented with IL-2 (100U/ml). After 
5 days, 10µl of MTT reagent 5mg/ml (Sigma Aldrich, 
57360-69-7) was added to each well and the plates were 
incubated for 4 hours at 37°C in a CO2 incubator. After 
incubation, 100μl of medium was aspirated and 100μl 
of Lysis Buffer (10% SDS and 0.01M HCL in H2O) was 
added to each well. The absorbance of each sample was 
measured at 570nm using a microplate reader.
nK cell proliferation
NK cells were plated in 96-well plates (1x106/ml) 
and cultured in complete medium with IL-2, IL-15 or IL-
15/IL-18 either in the presence or in the absence of the 
indicated drugs. After 6 days, NK cell proliferation was 
assessed using a Ki-67 staining protocol. Intranuclear 
staining was carried out using the FoxP3 permeabilization 
solution kit according to the manufacturer’s instructions 
(eBioscience, BMS00-5223-56). Ki-67 mAb was added 
and cells were incubated at 4°C for 30 minutes. Finally, 
the cells were washed twice, re-suspended in 1ml of 
1% fixation buffer, and analyzed by flow cytometry 
(FACSCalibur, BD). 
cytolytic assays and cytokine production
Fresh or activated NK cells were cultured in 
complete medium in the presence or in the absence of 
BRAF-i (PLX4032) or MEK-i (PD0325901) were tested 
for cytolytic activity in a 4-hour 51Cr-release assay against 
four human melanoma cell lines (i.e MeCoP, MeTA, 
MeDeBO and FO-1). The E:T ratios are indicated in the 
figures. The supernatants derived from both untreated 
and drug-treated NK cells were harvested, centrifuged 
to remove any cells or debris, and frozen at -80°C until 
assayed. Production of IFNγ was measured from NK-
derived supernatants with by commercial ELISA kits 
(ThermoFischer SCIENTIFIC, KHC4021C) following the 
manufacturers’ instructions.
Melanoma cell lines
Primary melanoma cell lines MeCoP, MeTA, 
MeDeBO, and MeOV were originated from metastatic 
lesions obtained in accordance with consent procedures 
(n.OMA09.001) approved by the Internal Ethics Board of 
the National Cancer Institute (IST, Genoa, Italy). Tissue 
specimens were processed for establishment of the cell 
lines as previously described [47]. FO-1 cell line was 
provided by Dr. Ferrone (New York Medical College). We 
confirmed and authenticated FO-1 cell line in our lab by 
PCR-SSP HLA class I typing (HLA-A25, -B08, -Bw6, and 
-Cw7) [54, 55].
statistical analysis
Statistical analyses were performed using the Prism 
software package (release 5.00; GraphPad Software). 
Statistical significance was evaluated by Student’s t test. 
A P value of less than 0.05 (*), less than 0.01 (**), or less 
than 0.001 (***) was considered statistically significant.
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